在第3阶段的LUCENT计划中,在性结肠炎患者中使用Mirikizumab进行早期和持续的症状控制
Silvio Danese1, Axel Dignass2, Katsuyoshi Matsuoka3
1Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milano, Italy.
Journal of Crohn's & colitis
|June 13, 2024
概括
米里基祖马布在几周内有效控制了性结肠炎症状,包括便频率和直肠出血,并在52周内维持了这种改善. 这种抗IL-23p19抗体在实现UC患者综合性症状控制方面表现出显著的有效性.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 性结肠炎 (UC) 是一种具有衰弱症状的慢性炎症性肠病.
- 抗列金-23p19抗体Mirikizumab在治疗UC时表现出有前途的结果.
- 之前的试验 (LUCENT-1/-2) 确立了mirikizumab的疗效和安全性.
研究的目的:
- 评估mirikizumab在实现UC患者症状控制方面的疗效.
- 评估诱导和维护阶段症状改善的时间.
- 确定实现全面的症状控制,并确定早期缓解的预后指标.
主要方法:
- 从LUCENT第3期试验 (LUCENT-1和LUCENT-2) 的数据分析.
- 超过52周的症状终点与安慰剂的比较.
- 对先前有生物或托法西提尼布失效的患者进行子组分析,并对预后指标进行回归分析.
主要成果:
- 在第二周,米里基祖马布迅速减少了便频率,直肠出血,肠急性和疲劳.
- 到第4周,腹部疼痛显著改善.
- 与安慰剂相比,在第12周和第52周,使用mirikizumab实现了更高的症状缓解率和全面的症状控制,并持续在整个维持期内.
结论:
- 米里基祖马布在中度至重度活跃UC的患者中实现和维持症状控制方面表现出显著的疗效.
- 反IL-23p19抗体在52周内提供了全面的症状控制.
- 治疗效应在患者子组中一致,包括那些先前治疗失败的患者.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
135
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
135
01:21Drugs for Treatment of Constipation-Predominant IBS
155
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
155
01:17Drugs for Treatment of Diarrhea-Predominant IBS
157
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
157
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130